Exelixis Inc (EXEL) stock news · P/E 20, rev $2.32B
Exelixis Inc (EXEL) is a biotechnology company listed on US.
This EXEL news page leads with what Exelixis Inc filed — not a scraped headline mill.
No cached 8-K sentence for EXEL yet. We will not pad this page with generic market recap.
Latest reported EXEL revenue for 2026-01-02 was $2.32B. Net income was $782.6M. Revenue was up 7.0% from 2025-01-03 to 2026-01-02. EXEL currently screens at market cap $12.69B and trailing P/E 19.6.
EDGAR remains the official archive. Lician caches the exhibit so you can read what changed without a wire story.
Not investment advice. For the model open the EXEL stock page; for the tape open the quote page.
EXEL stock news FAQ
What are EXEL's latest revenue and net income?
Latest cached Exelixis Inc (EXEL) revenue for Jan 2, 2026 was $2.32B. Net income was $782.6M. Statements: https://lician.com/financials/exel
How did EXEL revenue change from the prior cached period?
Cached Exelixis Inc (EXEL) revenue was up 7.0% from $2.17B (Jan 3, 2025) to $2.32B (Jan 2, 2026). Statements: https://lician.com/financials/exel
What is EXEL's P/E ratio?
Exelixis Inc (EXEL) trailing P/E is 19.6 on the latest cached fundamentals snapshot.
What is EXEL's market cap?
Exelixis Inc (EXEL) market cap is $12.69B on the latest cached fundamentals snapshot.
What kind of company is EXEL?
Exelixis Inc (EXEL) is a biotechnology company listed on US.
Where is EXEL stock news listed?
Cached stock news for Exelixis Inc (EXEL) is listed at https://lician.com/news/exel. Filings: https://lician.com/sec/exel
Not investment advice.